Overexpressed oncogenic tumor-self antigens

References

• American Cancer Society. Cancer Facts & Figures 2013. Atlanta: American Cancer Society; 2013.
   Google Scholar
• Mellman I, Coukos G, Dranoff G. Cancer immunotherapy comes of age. Nature 2011; 480:480-9; PMID:22193102; http://dx.doi.org/10.1038/nature10673
   PubMed Web of Science ®Google Scholar
• Couzin-Frankel J. Breakthrough of the year 2013. Cancer immunotherapy. Science 2013; 342:1432-3; PMID:24357284; http://dx.doi.org/10.1126/science.342.6165.1432
   PubMed Web of Science ®Google Scholar
• Weber JS, Kähler KC, Hauschild A. Management of immune-related adverse events and kinetics of response with ipilimumab. J Clin Oncol 2012; 30:2691-7; PMID:22614989; http://dx.doi.org/10.1200/JCO.2012.41.6750
   PubMed Web of Science ®Google Scholar
• Restifo NP, Dudley ME, Rosenberg SA. Adoptive immunotherapy for cancer: harnessing the T cell response. Nat Rev Immunol 2012; 12:269-81; PMID:22437939; http://dx.doi.org/10.1038/nri3191
   PubMed Web of Science ®Google Scholar
• Lewis JD, Reilly BD, Bright RK. Tumor-associated antigens: from discovery to immunity. Int Rev Immunol 2003; 22:81-112; PMID:12962271; http://dx.doi.org/10.1080/08830180305221
   PubMed Web of Science ®Google Scholar
• Schiller JT, Castellsagué X, Garland SM. A review of clinical trials of human papillomavirus prophylactic vaccines. Vaccine 2012; 30(Suppl 5):F123-38; PMID:23199956; http://dx.doi.org/10.1016/j.vaccine.2012.04.108
   PubMed Web of Science ®Google Scholar
• Ogi C, Aruga A. Clinical evaluation of therapeutic cancer vaccines. Hum Vaccin Immunother 2013; 9:1049-57; PMID:23454867; http://dx.doi.org/10.4161/hv.23917
   PubMed Web of Science ®Google Scholar
• Weiner LM, Surana R, Murray J. Vaccine prevention of cancer: can endogenous antigens be targeted? Cancer Prev Res (Phila) 2010; 3:410-5; PMID:20332297; http://dx.doi.org/10.1158/1940-6207.CAPR-10-0040
   PubMed Web of Science ®Google Scholar
• Michael A, Relph K, Annels N, Pandha H. Prostate cancer vaccines. Expert Rev Vaccines 2013; 12:253-62; PMID:23496665; http://dx.doi.org/10.1586/erv.13.27
   PubMed Web of Science ®Google Scholar
• Aranda F, Vacchelli E, Eggermont A, Galon J, Sautès-Fridman C, Tartour E, Zitvogel L, Kroemer G, Galluzzi L. Trial Watch: Peptide vaccines in cancer therapy. Oncoimmunology 2013; 2:e26621; PMID:24498550; http://dx.doi.org/10.4161/onci.26621
   PubMed Web of Science ®Google Scholar
• Mesri EA, Feitelson MA, Munger K. Human viral oncogenesis: a cancer hallmarks analysis. Cell Host Microbe 2014; 15:266-82; PMID:24629334; http://dx.doi.org/10.1016/j.chom.2014.02.011
   PubMed Web of Science ®Google Scholar
• Coggin JH Jr., Barsoum AL, Rohrer JW, Thurnher M, Zeis M. Contemporary definitions of tumor specific antigens, immunogens and markers as related to the adaptive responses of the cancer-bearing host. Anticancer Res 2005; 25(3c):2345-55; PMID:16080461
   PubMed Web of Science ®Google Scholar
• Yang JC. The adoptive transfer of cultured T cells for patients with metastatic melanoma. Clin Dermatol 2013; 31:209-19; PMID:23438384; http://dx.doi.org/10.1016/j.clindermatol.2012.08.019
   PubMed Web of Science ®Google Scholar
• Kulkarni P, Shiraishi T, Rajagopalan K, Kim R, Mooney SM, Getzenberg RH. Cancer/testis antigens and urological malignancies. Nat Rev Urol 2012; 9:386-96; PMID:22710665; http://dx.doi.org/10.1038/nrurol.2012.117
   PubMed Web of Science ®Google Scholar
• Coulie PG, Van den Eynde BJ, van der Bruggen P, Boon T. Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy. Nat Rev Cancer 2014; 14:135-46; PMID:24457417; http://dx.doi.org/10.1038/nrc3670
   PubMed Web of Science ®Google Scholar
• Cheever MA, Allison JP, Ferris AS, Finn OJ, Hastings BM, Hecht TT, Mellman I, Prindiville SA, Viner JL, Weiner LM, et al. The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research. Clin Cancer Res 2009; 15:5323-37; PMID:19723653; http://dx.doi.org/10.1158/1078-0432.CCR-09-0737
   PubMed Web of Science ®Google Scholar
• Augello MA, Den RB, Knudsen KE. AR function in promoting metastatic prostate cancer. [epub ahead of print]. Cancer Metastasis Rev 2014; PMID:24425228; http://dx.doi.org/10.1007/s10555-013-9471-3
   PubMed Web of Science ®Google Scholar
• McNamara KM, Yoda T, Nurani AM, Shibahara Y, Miki Y, Wang L, Nakamura Y, Suzuki K, Yang Y, Abe E, et al. Androgenic pathways in the progression of triple-negative breast carcinoma: a comparison between aggressive and non-aggressive subtypes. [epub ahead of print]. Breast Cancer Res Treat 2014; 145:281-93; PMID:24715382; http://dx.doi.org/10.1007/s10549-014-2942-6
   PubMed Web of Science ®Google Scholar
• Olson BM, McNeel DG. Antibody and T-cell responses specific for the androgen receptor in patients with prostate cancer. Prostate 2007; 67:1729-39; PMID:17879963; http://dx.doi.org/10.1002/pros.20652
   PubMed Web of Science ®Google Scholar
• Olson BM, McNeel DG. CD8+ T cells specific for the androgen receptor are common in patients with prostate cancer and are able to lyse prostate tumor cells. Cancer Immunol Immunother 2011; 60:781-92; PMID:21350948; http://dx.doi.org/10.1007/s00262-011-0987-5
   PubMed Web of Science ®Google Scholar
• Olson BM, Johnson LE, McNeel DG. The androgen receptor: a biologically relevant vaccine target for the treatment of prostate cancer. Cancer Immunol Immunother 2013; 62:585-96; PMID:23108626; http://dx.doi.org/10.1007/s00262-012-1363-9
   PubMed Web of Science ®Google Scholar
• Seliger B, Kono K, Rongcun Y, Kiessling R. Cytotoxic T cell epitopes and tissue distribution of the HER-2/neu proto-oncogene: Implications for vaccine development. In W.M. Kast (Ed.) Peptide-based Cancer Vaccines. Georgetown, TX: Eurekah.com & Landes Bioscience, 2000.
   Google Scholar
• Disis ML, Cheever MA. Clinical trials of HER-2/neu peptide-based vaccines. In W.M. Kast (Ed.) Peptide-based Cancer Vaccines. Georgetown, Texas: Eurekah.com & Landes Bioscience, 2000.
   Google Scholar
• Wiedermann U, Davis AB, Zielinski CC. Vaccination for the prevention and treatment of breast cancer with special focus on Her-2/neu peptide vaccines. Breast Cancer Res Treat 2013; 138:1-12; PMID:23340862; http://dx.doi.org/10.1007/s10549-013-2410-8
   PubMed Web of Science ®Google Scholar
• Linehan DC, Goedegebuure PS, Peoples GE, Rogers SO, Eberlein TJ. Tumor-specific and HLA-A2-restricted cytolysis by tumor-associated lymphocytes in human metastatic breast cancer. J Immunol 1995; 155:4486-91; PMID:7594611
   PubMed Web of Science ®Google Scholar
• Baxevanis CN, Voutsas IF, Gritzapis AD, Perez SA, Papamichail M. HER-2/neu as a target for cancer vaccines. Immunotherapy 2010; 2:213-26; PMID:20635929; http://dx.doi.org/10.2217/imt.09.89
   PubMed Web of Science ®Google Scholar
• Levine AJ. p53, the cellular gatekeeper for growth and division. Cell 1997; 88:323-31; PMID:9039259; http://dx.doi.org/10.1016/S0092-8674(00)81871-1
   PubMed Web of Science ®Google Scholar
• Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutations in human cancers. Science 1991; 253:49-53; PMID:1905840; http://dx.doi.org/10.1126/science.1905840
   PubMed Web of Science ®Google Scholar
• Vierboom MPM, Nijman HW, Offringa R, van der Voort EI, van Hall T, van den Broek L, Fleuren GJ, Kenemans P, Kast WM, Melief CJ. Tumor eradication by wild-type p53-specific cytotoxic T lymphocytes. J Exp Med 1997; 186:695-704; PMID:9271585; http://dx.doi.org/10.1084/jem.186.5.695
   PubMed Web of Science ®Google Scholar
• Hoffmann TK, Donnenberg AD, Finkelstein SD, Donnenberg VS, Friebe-Hoffmann U, Myers EN, Appella E, DeLeo AB, Whiteside TL. Frequencies of tetramer+ T cells specific for the wild-type sequence p53(264-272) peptide in the circulation of patients with head and neck cancer. Cancer Res 2002; 62:3521-9; PMID:12067999
   PubMed Web of Science ®Google Scholar
• Pedersen AE, Stryhn A, Justesen S, Harndahl M, Rasmussen S, Donskov F, Claesson MH, Pedersen JW, Wandall HH, Svane IM, et al. Wildtype p53-specific antibody and T-cell responses in cancer patients. J Immunother 2011; 34:629-40; PMID:21989411; http://dx.doi.org/10.1097/CJI.0b013e3182281381
   PubMed Web of Science ®Google Scholar
• Leffers N, Vermeij R, Hoogeboom BN, Schulze UR, Wolf R, Hamming IE, van der Zee AG, Melief KJ, van der Burg SH, Daemen T, et al. Long-term clinical and immunological effects of p53-SLP® vaccine in patients with ovarian cancer. Int J Cancer 2012; 130:105-12; PMID:21328579; http://dx.doi.org/10.1002/ijc.25980
   PubMed Web of Science ®Google Scholar
• Rahma OE, Ashtar E, Czystowska M, Szajnik ME, Wieckowski E, Bernstein S, Herrin VE, Shams MA, Steinberg SM, Merino M, et al. A gynecologic oncology group phase II trial of two p53 peptide vaccine approaches: subcutaneous injection and intravenous pulsed dendritic cells in high recurrence risk ovarian cancer patients. Cancer Immunol Immunother 2012; 61:373-84; PMID:21927947; http://dx.doi.org/10.1007/s00262-011-1100-9
   PubMed Web of Science ®Google Scholar
• Zeestraten EC, Speetjens FM, Welters MJ, Saadatmand S, Stynenbosch LF, Jongen R, Kapiteijn E, Gelderblom H, Nijman HW, Valentijn AR, et al. Addition of interferon-α to the p53-SLP® vaccine results in increased production of interferon-γ in vaccinated colorectal cancer patients: a phase I/II clinical trial. Int J Cancer 2013; 132:1581-91; PMID:22948952; http://dx.doi.org/10.1002/ijc.27819
   PubMed Web of Science ®Google Scholar
• Hall RD, Gray JE, Chiappori AA. Beyond the standard of care: a review of novel immunotherapy trials for the treatment of lung cancer. Cancer Control 2013; 20:22-31; PMID:23302904
   PubMed Web of Science ®Google Scholar
• Iclozan C, Antonia S, Chiappori A, Chen DT, Gabrilovich D. Therapeutic regulation of myeloid-derived suppressor cells and immune response to cancer vaccine in patients with extensive stage small cell lung cancer. Cancer Immunol Immunother 2013; 62:909-18; PMID:23589106; http://dx.doi.org/10.1007/s00262-013-1396-8
   PubMed Web of Science ®Google Scholar
• Vermeij R, Leffers N, Melief CJ, Daemen T, Nijman HW. Antigen-specific immunotherapy in ovarian cancer and p53 as tumor antigen. Curr Pharm Des 2012; 18:3804-11; PMID:22591425; http://dx.doi.org/10.2174/138161212802002805
   PubMed Web of Science ®Google Scholar
• Park JE, Son AI, Zhou R. Roles of EphA2 in development and disease. Genes (Basel) 2013; 4:334-57; PMID:24705208; http://dx.doi.org/10.3390/genes4030334
   PubMed Web of Science ®Google Scholar
• Wykosky J, Debinski W. The EphA2 receptor and ephrinA1 ligand in solid tumors: function and therapeutic targeting. Mol Cancer Res 2008; 6:1795-806; PMID:19074825; http://dx.doi.org/10.1158/1541-7786.MCR-08-0244
   PubMed Web of Science ®Google Scholar
• Hatano M, Eguchi J, Tatsumi T, Kuwashima N, Dusak JE, Kinch MS, Pollack IF, Hamilton RL, Storkus WJ, Okada H. EphA2 as a glioma-associated antigen: a novel target for glioma vaccines. Neoplasia 2005; 7:717-22; PMID:16207473; http://dx.doi.org/10.1593/neo.05277
   PubMed Web of Science ®Google Scholar
• Yamaguchi S, Tatsumi T, Takehara T, Sakamori R, Uemura A, Mizushima T, Ohkawa K, Storkus WJ, Hayashi N. Immunotherapy of murine colon cancer using receptor tyrosine kinase EphA2-derived peptide-pulsed dendritic cell vaccines. Cancer 2007; 110:1469-77; PMID:17685394; http://dx.doi.org/10.1002/cncr.22958
   PubMed Web of Science ®Google Scholar
• Yamaguchi S, Tatsumi T, Takehara T, Sasakawa A, Hikita H, Kohga K, Uemura A, Sakamori R, Ohkawa K, Hayashi N. Dendritic cell-based vaccines suppress metastatic liver tumor via activation of local innate and acquired immunity. Cancer Immunol Immunother 2008; 57:1861-9; PMID:18438665; http://dx.doi.org/10.1007/s00262-008-0514-5
   PubMed Web of Science ®Google Scholar
• Ueda R, Fujita M, Zhu X, Sasaki K, Kastenhuber ER, Kohanbash G, McDonald HA, Harper J, Lonning S, Okada H. Systemic inhibition of transforming growth factor-beta in glioma-bearing mice improves the therapeutic efficacy of glioma-associated antigen peptide vaccines. Clin Cancer Res 2009; 15:6551-9; PMID:19861464; http://dx.doi.org/10.1158/1078-0432.CCR-09-1067
   PubMed Web of Science ®Google Scholar
• Yeung JT, Hamilton RL, Okada H, Jakacki RI, Pollack IF. Increased expression of tumor-associated antigens in pediatric and adult ependymomas: implication for vaccine therapy. J Neurooncol 2013; 111:103-11; PMID:23179498; http://dx.doi.org/10.1007/s11060-012-0998-x
   PubMed Web of Science ®Google Scholar
• Okada H, Kalinski P, Ueda R, Hoji A, Kohanbash G, Donegan TE, Mintz AH, Engh JA, Bartlett DL, Brown CK, et al. Induction of CD8+ T-cell responses against novel glioma-associated antigen peptides and clinical activity by vaccinations with alpha-type 1 polarized dendritic cells and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in patients with recurrent malignant glioma. J Clin Oncol 2011; 29:330-6; PMID:21149657; http://dx.doi.org/10.1200/JCO.2010.30.7744
   PubMed Web of Science ®Google Scholar
• Bodnar AG, Ouellette M, Frolkis M, Holt SE, Chiu CP, Morin GB, Harley CB, Shay JW, Lichtsteiner S, Wright WE. Extension of life-span by introduction of telomerase into normal human cells. Science 1998; 279:349-52; PMID:9454332; http://dx.doi.org/10.1126/science.279.5349.349
   PubMed Web of Science ®Google Scholar
• Meyerson M, Counter CM, Eaton EN, Ellisen LW, Steiner P, Caddle SD, Ziaugra L, Beijersbergen RL, Davidoff MJ, Liu Q, et al. hEST2, the putative human telomerase catalytic subunit gene, is up-regulated in tumor cells and during immortalization. Cell 1997; 90:785-95; PMID:9288757; http://dx.doi.org/10.1016/S0092-8674(00)80538-3
   PubMed Web of Science ®Google Scholar
• Beatty GL, Vonderheide RH. Telomerase as a universal tumor antigen for cancer vaccines. Expert Rev Vaccines 2008; 7:881-7; PMID:18767939; http://dx.doi.org/10.1586/14760584.7.7.881
   PubMed Web of Science ®Google Scholar
• Vonderheide RH, Hahn WC, Schultze JL, Nadler LM. The telomerase catalytic subunit is a widely expressed tumor-associated antigen recognized by cytotoxic T lymphocytes. Immunity 1999; 10:673-9; PMID:10403642; http://dx.doi.org/10.1016/S1074-7613(00)80066-7
   PubMed Web of Science ®Google Scholar
• Filaci G, Fravega M, Setti M, Traverso P, Millo E, Fenoglio D, Negrini S, Ferrera F, Romagnoli A, Basso M, et al. Frequency of telomerase-specific CD8+ T lymphocytes in patients with cancer. Blood 2006; 107:1505-12; PMID:16249379; http://dx.doi.org/10.1182/blood-2005-01-0258
   PubMed Web of Science ®Google Scholar
• Carpenter EL, Vonderheide RH. Telomerase-based immunotherapy of cancer. Expert Opin Biol Ther 2006; 6:1031-9; PMID:16989585; http://dx.doi.org/10.1517/14712598.6.10.1031
   PubMed Web of Science ®Google Scholar
• Kyte JA. Cancer vaccination with telomerase peptide GV1001. Expert Opin Investig Drugs 2009; 18:687-94; PMID:19388882; http://dx.doi.org/10.1517/13543780902897631
   PubMed Web of Science ®Google Scholar
• Vonderheide RH, Domchek SM, Schultze JL, George DJ, Hoar KM, Chen DY, Stephans KF, Masutomi K, Loda M, Xia Z, et al. Vaccination of cancer patients against telomerase induces functional antitumor CD8+ T lymphocytes. Clin Cancer Res 2004; 10:828-39; PMID:14871958; http://dx.doi.org/10.1158/1078-0432.CCR-0620-3
   PubMed Web of Science ®Google Scholar
• Immunological and Clinical Outcomes following telomerase peptide vaccination in patients with metastatic breast cancer. Proc. Am. As. Cancer Res 2006; 4003a
   Google Scholar
• Brunsvig PF, Aamdal S, Gjertsen MK, Kvalheim G, Markowski-Grimsrud CJ, Sve I, Dyrhaug M, Trachsel S, Møller M, Eriksen JA, et al. Telomerase peptide vaccination: a phase I/II study in patients with non-small cell lung cancer. Cancer Immunol Immunother 2006; 55:1553-64; PMID:16491401; http://dx.doi.org/10.1007/s00262-006-0145-7
   PubMed Web of Science ®Google Scholar
• Su Z, Dannull J, Yang BK, Dahm P, Coleman D, Yancey D, Sichi S, Niedzwiecki D, Boczkowski D, Gilboa E, et al. Telomerase mRNA-transfected dendritic cells stimulate antigen-specific CD8+ and CD4+ T cell responses in patients with metastatic prostate cancer. J Immunol 2005; 174:3798-807; PMID:15749921; http://dx.doi.org/10.4049/jimmunol.174.6.3798
   PubMed Web of Science ®Google Scholar
• Brunsvig PF, Kyte JA, Kersten C, Sundstrøm S, Møller M, Nyakas M, Hansen GL, Gaudernack G, Aamdal S. Telomerase peptide vaccination in NSCLC: a phase II trial in stage III patients vaccinated after chemoradiotherapy and an 8-year update on a phase I/II trial. Clin Cancer Res 2011; 17:6847-57; PMID:21918169; http://dx.doi.org/10.1158/1078-0432.CCR-11-1385
   PubMed Web of Science ®Google Scholar
• Hunger RE, Kernland Lang K, Markowski CJ, Trachsel S, Møller M, Eriksen JA, Rasmussen AM, Braathen LR, Gaudernack G. Vaccination of patients with cutaneous melanoma with telomerase-specific peptides. Cancer Immunol Immunother 2011; 60:1553-64; PMID:21681371; http://dx.doi.org/10.1007/s00262-011-1061-z
   PubMed Web of Science ®Google Scholar
• Inderberg-Suso EM, Trachsel S, Lislerud K, Rasmussen AM, Gaudernack G. Widespread CD4+ T-cell reactivity to novel hTERT epitopes following vaccination of cancer patients with a single hTERT peptide GV1001. Oncoimmunology 2012; 1:670-86; PMID:22934259; http://dx.doi.org/10.4161/onci.20426
   PubMed Web of Science ®Google Scholar
• Fenoglio D, Traverso P, Parodi A, Tomasello L, Negrini S, Kalli F, Battaglia F, Ferrera F, Sciallero S, Murdaca G, et al. A multi-peptide, dual-adjuvant telomerase vaccine (GX301) is highly immunogenic in patients with prostate and renal cancer. Cancer Immunol Immunother 2013; 62:1041-52; PMID:23591981; http://dx.doi.org/10.1007/s00262-013-1415-9
   PubMed Web of Science ®Google Scholar
• Vetsika EK, Konsolakis G, Aggouraki D, Kotsakis A, Papadimitraki E, Christou S, Menez-Jamet J, Kosmatopoulos K, Georgoulias V, Mavroudis D. Immunological responses in cancer patients after vaccination with the therapeutic telomerase-specific vaccine Vx-001. Cancer Immunol Immunother 2012; 61:157-68; PMID:21858533; http://dx.doi.org/10.1007/s00262-011-1093-4
   PubMed Web of Science ®Google Scholar
• LaCasse EC, Baird S, Korneluk RG, MacKenzie AE. The inhibitors of apoptosis (IAPs) and their emerging role in cancer. Oncogene 1998; 17:3247-59; PMID:9916987; http://dx.doi.org/10.1038/sj.onc.1202569
   PubMed Web of Science ®Google Scholar
• Stauber RH, Mann W, Knauer SK. Nuclear and cytoplasmic survivin: molecular mechanism, prognostic, and therapeutic potential. Cancer Res 2007; 67:5999-6002; PMID:17616652; http://dx.doi.org/10.1158/0008-5472.CAN-07-0494
   PubMed Web of Science ®Google Scholar
• Adida C, Haioun C, Gaulard P, Lepage E, Morel P, Briere J, Dombret H, Reyes F, Diebold J, Gisselbrecht C, et al. Prognostic significance of survivin expression in diffuse large B-cell lymphomas. Blood 2000; 96:1921-5; PMID:10961895
   PubMed Web of Science ®Google Scholar
• Schmidt SM, Schag K, Müller MR, Weck MM, Appel S, Kanz L, Grünebach F, Brossart P. Survivin is a shared tumor-associated antigen expressed in a broad variety of malignancies and recognized by specific cytotoxic T cells. Blood 2003; 102:571-6; PMID:12576330; http://dx.doi.org/10.1182/blood-2002-08-2554
   PubMed Web of Science ®Google Scholar
• Andersen MH, thor SP. Survivin–a universal tumor antigen. Histol Histopathol 2002; 17:669-75; PMID:11962766
   PubMed Web of Science ®Google Scholar
• Andersen MH, Svane IM, Becker JC, Straten PT. The universal character of the tumor-associated antigen survivin. Clin Cancer Res 2007; 13:5991-4; PMID:17947459; http://dx.doi.org/10.1158/1078-0432.CCR-07-0686
   PubMed Web of Science ®Google Scholar
• Schmitz M, Diestelkoetter P, Weigle B, Schmachtenberg F, Stevanovic S, Ockert D, Rammensee HG, Rieber EP. Generation of survivin-specific CD8+ T effector cells by dendritic cells pulsed with protein or selected peptides. Cancer Res 2000; 60:4845-9; PMID:10987296
   PubMed Web of Science ®Google Scholar
• Andersen MH, Pedersen LO, Becker JC, Straten PT. Identification of a cytotoxic T lymphocyte response to the apoptosis inhibitor protein survivin in cancer patients. Cancer Res 2001; 61:869-72; PMID:11221872
   PubMed Web of Science ®Google Scholar
• Kameshima H, Tsuruma T, Kutomi G, Shima H, Iwayama Y, Kimura Y, Imamura M, Torigoe T, Takahashi A, Hirohashi Y, et al. Immunotherapeutic benefit of α-interferon (IFNα) in survivin2B-derived peptide vaccination for advanced pancreatic cancer patients. Cancer Sci 2013; 104:124-9; PMID:23078230; http://dx.doi.org/10.1111/cas.12046
   PubMed Web of Science ®Google Scholar
• Filipazzi P, Pilla L, Mariani L, Patuzzo R, Castelli C, Camisaschi C, Maurichi A, Cova A, Rigamonti G, Giardino F, et al. Limited induction of tumor cross-reactive T cells without a measurable clinical benefit in early melanoma patients vaccinated with human leukocyte antigen class I-modified peptides. Clin Cancer Res 2012; 18:6485-96; PMID:23032742; http://dx.doi.org/10.1158/1078-0432.CCR-12-1516
   PubMed Web of Science ®Google Scholar
• Becker JC, Andersen MH, Hofmeister-Müller V, Wobser M, Frey L, Sandig C, Walter S, Singh-Jasuja H, Kämpgen E, Opitz A, et al. Survivin-specific T-cell reactivity correlates with tumor response and patient survival: a phase-II peptide vaccination trial in metastatic melanoma. Cancer Immunol Immunother 2012; 61:2091-103; PMID:22565484; http://dx.doi.org/10.1007/s00262-012-1266-9
   PubMed Web of Science ®Google Scholar
• Scanlan MJ, Gout I, Gordon CM, Williamson B, Stockert E, Gure AO, Jäger D, Chen YT, Mackay A, O’Hare MJ, et al. Humoral immunity to human breast cancer: antigen definition and quantitative analysis of mRNA expression. Cancer Immun 2001; 1:4; PMID:12747765
   PubMedGoogle Scholar
• Anderson KS, Sibani S, Wallstrom G, Qiu J, Mendoza EA, Raphael J, Hainsworth E, Montor WR, Wong J, Park JG, et al. Protein microarray signature of autoantibody biomarkers for the early detection of breast cancer. J Proteome Res 2011; 10:85-96; PMID:20977275; http://dx.doi.org/10.1021/pr100686b
   PubMed Web of Science ®Google Scholar
• Balleine RL, Fejzo MS, Sathasivam P, Basset P, Clarke CL, Byrne JA. The hD52 (TPD52) gene is a candidate target gene for events resulting in increased 8q21 copy number in human breast carcinoma. Genes Chromosomes Cancer 2000; 29:48-57; PMID:10918393; http://dx.doi.org/10.1002/1098-2264(2000)9999:9999≤::AID-GCC1005≥3.0.CO;2-O
   PubMed Web of Science ®Google Scholar
• Byrne JA, Tomasetto C, Garnier JM, Rouyer N, Mattei MG, Bellocq JP, Rio MC, Basset P. A screening method to identify genes commonly overexpressed in carcinomas and the identification of a novel complementary DNA sequence. Cancer Res 1995; 55:2896-903; PMID:7796418
   PubMed Web of Science ®Google Scholar
• Pollack JR, Sørlie T, Perou CM, Rees CA, Jeffrey SS, Lonning PE, Tibshirani R, Botstein D, Børresen-Dale AL, Brown PO. Microarray analysis reveals a major direct role of DNA copy number alteration in the transcriptional program of human breast tumors. Proc Natl Acad Sci U S A 2002; 99:12963-8; PMID:12297621; http://dx.doi.org/10.1073/pnas.162471999
   PubMed Web of Science ®Google Scholar
• Wang R, Xu J, Saramäki O, Visakorpi T, Sutherland WM, Zhou J, Sen B, Lim SD, Mabjeesh N, Amin M, et al. PrLZ, a novel prostate-specific and androgen-responsive gene of the TPD52 family, amplified in chromosome 8q21.1 and overexpressed in human prostate cancer. Cancer Res 2004; 64:1589-94; PMID:14996714; http://dx.doi.org/10.1158/0008-5472.CAN-03-3331
   PubMed Web of Science ®Google Scholar
• Wang R, Xu J, Mabjeesh N, Zhu G, Zhou J, Amin M, He D, Marshall FF, Zhau HE, Chung LW. PrLZ is expressed in normal prostate development and in human prostate cancer progression. Clin Cancer Res 2007; 13:6040-8; PMID:17947466; http://dx.doi.org/10.1158/1078-0432.CCR-07-0640
   PubMed Web of Science ®Google Scholar
• Rubin MA, Varambally S, Beroukhim R, Tomlins SA, Rhodes DR, Paris PL, Hofer MD, Storz-Schweizer M, Kuefer R, Fletcher JA, et al. Overexpression, amplification, and androgen regulation of TPD52 in prostate cancer. Cancer Res 2004; 64:3814-22; PMID:15172988; http://dx.doi.org/10.1158/0008-5472.CAN-03-3881
   PubMed Web of Science ®Google Scholar
• Byrne JA, Balleine RL, Schoenberg Fejzo M, Mercieca J, Chiew YE, Livnat Y, St Heaps L, Peters GB, Byth K, Karlan BY, et al. Tumor protein D52 (TPD52) is overexpressed and a gene amplification target in ovarian cancer. Int J Cancer 2005; 117:1049-54; PMID:15986428; http://dx.doi.org/10.1002/ijc.21250
   PubMed Web of Science ®Google Scholar
• Largo C, Alvarez S, Saez B, Blesa D, Martin-Subero JI, González-García I, Brieva JA, Dopazo J, Siebert R, Calasanz MJ, et al. Identification of overexpressed genes in frequently gained/amplified chromosome regions in multiple myeloma. Haematologica 2006; 91:184-91; PMID:16461302
   PubMed Web of Science ®Google Scholar
• Tiacci E, Orvietani PL, Bigerna B, Pucciarini A, Corthals GL, Pettirossi V, Martelli MP, Liso A, Benedetti R, Pacini R, et al. Tumor protein D52 (TPD52): a novel B-cell/plasma-cell molecule with unique expression pattern and Ca(2+)-dependent association with annexin VI. Blood 2005; 105:2812-20; PMID:15576473; http://dx.doi.org/10.1182/blood-2004-07-2630
   PubMed Web of Science ®Google Scholar
• Dave SS, Fu K, Wright GW, Lam LT, Kluin P, Boerma EJ, Greiner TC, Weisenburger DD, Rosenwald A, Ott G, et al.; Lymphoma/Leukemia Molecular Profiling Project. Molecular diagnosis of Burkitt's lymphoma. N Engl J Med 2006; 354:2431-42; PMID:16760443; http://dx.doi.org/10.1056/NEJMoa055759
   PubMed Web of Science ®Google Scholar
• Hummel M, Bentink S, Berger H, Klapper W, Wessendorf S, Barth TF, Bernd HW, Cogliatti SB, Dierlamm J, Feller AC, et al.; Molecular Mechanisms in Malignant Lymphomas Network Project of the Deutsche Krebshilfe. A biologic definition of Burkitt's lymphoma from transcriptional and genomic profiling. N Engl J Med 2006; 354:2419-30; PMID:16760442; http://dx.doi.org/10.1056/NEJMoa055351
   PubMed Web of Science ®Google Scholar
• Loukopoulos P, Shibata T, Katoh H, Kokubu A, Sakamoto M, Yamazaki K, Kosuge T, Kanai Y, Hosoda F, Imoto I, et al. Genome-wide array-based comparative genomic hybridization analysis of pancreatic adenocarcinoma: identification of genetic indicators that predict patient outcome. Cancer Sci 2007; 98:392-400; PMID:17233815; http://dx.doi.org/10.1111/j.1349-7006.2007.00395.x
   PubMed Web of Science ®Google Scholar
• Skotheim RI, Autio R, Lind GE, Kraggerud SM, Andrews PW, Monni O, Kallioniemi O, Lothe RA. Novel genomic aberrations in testicular germ cell tumors by array-CGH, and associated gene expression changes. Cell Oncol 2006; 28:315-26; PMID:17167184
   PubMed Web of Science ®Google Scholar
• Korkola JE, Heck S, Olshen AB, Reuter VE, Bosl GJ, Houldsworth J, Chaganti RS. In vivo differentiation and genomic evolution in adult male germ cell tumors. Genes Chromosomes Cancer 2008; 47:43-55; PMID:17943972; http://dx.doi.org/10.1002/gcc.20504
   PubMed Web of Science ®Google Scholar
• McIntyre A, Summersgill B, Lu YJ, Missiaglia E, Kitazawa S, Oosterhuis JW, Looijenga LH, Shipley J. Genomic copy number and expression patterns in testicular germ cell tumours. Br J Cancer 2007; 97:1707-12; PMID:18059402; http://dx.doi.org/10.1038/sj.bjc.6604079
   PubMed Web of Science ®Google Scholar
• Hoek KS. DNA microarray analyses of melanoma gene expression: a decade in the mines. Pigment Cell Res 2007; 20:466-84; PMID:17935490; http://dx.doi.org/10.1111/j.1600-0749.2007.00412.x
   PubMedGoogle Scholar
• Roesch A, Becker B, Bentink S, Spang R, Vogl A, Hagen I, Landthaler M, Vogt T. Ataxia telangiectasia-mutated gene is a possible biomarker for discrimination of infiltrative deep penetrating nevi and metastatic vertical growth phase melanoma. Cancer Epidemiol Biomarkers Prev 2007; 16:2486-90; PMID:18006941; http://dx.doi.org/10.1158/1055-9965.EPI-07-0224
   PubMed Web of Science ®Google Scholar
• Byrne JA, Frost S, Chen Y, Bright RK. Tumor protein D52 (TPD52) and cancer-oncogene understudy or understudied oncogene? Tumour Biol 2014; 35(8):7369-82 PMID:24798974; http://dx.doi.org/10.1007/s13277-014-2006-x
   PubMed Web of Science ®Google Scholar
• Byrne JA, Mattei MG, Basset P. Definition of the D52 gene/protein family through cloning of D52 homologues in human (hD53) and mouse (mD52). Genomics 1996; 35:523-32; PMID:8812487; http://dx.doi.org/10.1006/geno.1996.0393
   PubMed Web of Science ®Google Scholar
• Lewis JD, Payton LA, Whitford JG, Byrne JA, Smith DI, Yang L, Bright RK. Induction of tumorigenesis and metastasis by the murine orthologue of tumor protein D52. Mol Cancer Res 2007; 5:133-44; PMID:17314271; http://dx.doi.org/10.1158/1541-7786.MCR-06-0245
   PubMed Web of Science ®Google Scholar
• Shehata M, Bièche I, Boutros R, Weidenhofer J, Fanayan S, Spalding L, Zeps N, Byth K, Bright RK, Lidereau R, et al. Nonredundant functions for tumor protein D52-like proteins support specific targeting of TPD52. Clin Cancer Res 2008; 14:5050-60; PMID:18698023; http://dx.doi.org/10.1158/1078-0432.CCR-07-4994
   PubMed Web of Science ®Google Scholar
• Payton LA, Lewis JD, Byrne JA, Bright RK. Vaccination with metastasis-related tumor associated antigen TPD52 and CpG/ODN induces protective tumor immunity. Cancer Immunol Immunother 2008; 57:799-811; PMID:17962942; http://dx.doi.org/10.1007/s00262-007-0416-y
   PubMed Web of Science ®Google Scholar
• Bright JD, Schultz HN, Byrne JA, Bright RK. Injection site and regulatory T cells influence durable vaccine-induced tumor immunity to an over-expressed self tumor associated antigen. Oncoimmunology 2013; 2:e25049; PMID:24073379; http://dx.doi.org/10.4161/onci.25049
   PubMedGoogle Scholar
• Lewis JD, Sullivan LA, Byrne JA, de Riese W, Bright RK. Memory and cellular immunity induced by a DNA vaccine encoding self antigen TPD52 administered with soluble GM-CSF. Cancer Immunol Immunother 2009; 58:1337-49; PMID:19169682; http://dx.doi.org/10.1007/s00262-009-0659-x
   PubMed Web of Science ®Google Scholar
• Bright JD, Aldrich JF, Byrne JA, Bright RK. Vaccination with the prostate cancer overexpressed tumor self-protein TPD52 elicits protective tumor immunity and a potentially unique subset of CD8+ T cells. Austin J Clin Immunol 2014; 1:1-13
   Google Scholar
• Mirshahidi S, Kramer VG, Whitney JB, Essono S, Lee S, Dranoff G, Anderson KS, Ruprecht RM. Overlapping synthetic peptides encoding TPD52 as breast cancer vaccine in mice: prolonged survival. Vaccine 2009; 27:1825-33; PMID:19201387; http://dx.doi.org/10.1016/j.vaccine.2009.01.089
   PubMed Web of Science ®Google Scholar
• Bright RK, Kimchi ET, Shearer MH, Kennedy RC, Pass HI. SV40 Tag-specific cytotoxic T lymphocytes generated from the peripheral blood of malignant pleural mesothelioma patients. Cancer Immunol Immunother 2002; 50:682-90; PMID:11862420; http://dx.doi.org/10.1007/s00262-001-0240-8
   PubMed Web of Science ®Google Scholar
• Bright RK, Vocke CD, Emmert-Buck MR, Duray PH, Solomon D, Fetsch P, Rhim JS, Linehan WM, Topalian SL. Generation and genetic characterization of immortal human prostate epithelial cell lines derived from primary cancer specimens. Cancer Res 1997; 57:995-1002; PMID:9041206
   PubMed Web of Science ®Google Scholar
• Duraiswamy J, Kaluza KM, Freeman GJ, Coukos G. Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors. Cancer Res 2013; 73:3591-603; PMID:23633484; http://dx.doi.org/10.1158/0008-5472.CAN-12-4100
   PubMed Web of Science ®Google Scholar